Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Study (Extension 001)to Evaluate Long Term Treatment Effect of the Safety, Tolerability and Efficacy of Intervenous ALPHA-1 ANTITRYPSIN (AAT) (Glasia) in Type 1 Diabetes Mellitus (Extension to KAMADA AAt 008, PHASE I/II Study)

Trial Profile

Open Label Study (Extension 001)to Evaluate Long Term Treatment Effect of the Safety, Tolerability and Efficacy of Intervenous ALPHA-1 ANTITRYPSIN (AAT) (Glasia) in Type 1 Diabetes Mellitus (Extension to KAMADA AAt 008, PHASE I/II Study)

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 10 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 02 Feb 2015 Results published in a Kamada media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top